References

1. Lageder H: [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia]. Wien Klin Wochenschr. 1980 Feb 1;92(3):95-101. [PubMed:6985560 ]
2. McCullough PA, Ahmed AB, Zughaib MT, Glanz ED, Di Loreto MJ: Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Rev Cardiovasc Med. 2011;12(4):173-85. doi: 10.3909/ricm0619. [PubMed:22249508 ]
3. Charach G, Grosskopf I, Rotmensch HH, Kitzis I, Weintraub M: Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease. Nephron Clin Pract. 2005;100(4):c120-5. Epub 2005 Apr 20. [PubMed:15849478 ]
4. Barbir M, Hunt B, Kushwaha S, Kehely A, Prescot R, Thompson GR, Mitchell A, Yacoub M: Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol. 1992 Dec 15;70(20):1596-601. [PubMed:1466329 ]
5. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D: Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000 Dec;15(12):1993-9. [PubMed:11096145 ]
6. MacCallum PK, Cooper JA, Rumley A, Lowe GD, Meade TW: Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost. 2004 Feb;2(2):364-5. [PubMed:14996019 ]